Latest Breaking News On - Atomwise atomnet - Page 1 : comparemela.com

Unveiling a new cardiac myosin inhibitor through AI-driven virtual screening

Discovery of a novel cardiac-specific myosin modulator.

Global (AI) Artificial Intelligence in Precision Medicine Market Size Will Grow Over USD 26.24 Billion By 2032, at 35.5% CAGR: Report by Polaris Market Research

/PRNewswire/ A latest research report [115+] pages with 360-Degree visibility, titled "Artificial Intelligence in Precision Medicine Market Share, Size,.

AI-based drug discovery with Atomwise and WEKA Data Platform

Atomwise Announces Growing Portfolio of Joint Venture Companies

Published: Dec 21, 2020 Dec. 21, 2020 21:37 UTC Atomwise unveils a growing portfolio of emerging joint venture companies, with programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Atomwise CEO and joint venture companies are scheduled to speak at Informa s Biotech Showcase from January 11-15, 2021 during J.P. Morgan Healthcare Week. Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, today unveiled its growing portfolio of emerging joint venture companies with research programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. In the area of infectious disease, the company is announcing the addition of vAirus, a newly formed joint venture company with world RNA-virus expert Nito Panganiban. The joint venture will use AI-based screening to find small molecule compounds to act as novel broad-spectrum antivirals against flaviviruses, a genus of RNA-viruse

Atomwise Announces Growing Portfolio of Joint Venture Companies – IT Business Net